Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)

Technology appraisal
Reference number: TA889
Published: 17 May 2023

History

Invitation to participate

Final scope (PDF 189 KB)

Published:

12 March 2021
Final stakeholder list (PDF 163 KB)

Published:

12 March 2021
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 228 KB)

Published:

12 March 2021
Equality impact assessment (Scoping) (PDF 123 KB)

Published:

12 March 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 211 KB)

Published:

01 February 2021
Draft matrix post referral (PDF 164 KB)

Published:

01 February 2021